Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJRK6D)

Drug Name

SB-9200 Drug Info

Synonyms

SB 9200

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis B virus infection	1E51.0	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Retinoic acid-inducible gene-1 (RIG-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CV8102	DMYD37G	Melanoma	2C30	Phase 1	[3]
MK-4621	DMN40DU	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
------------------------------------------------------------------------------------

Drug(s) Targeting Pattern recognition receptor NOD2 (NOD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MIS-416	DM7K4YR	Autoimmune diabetes	5A10	Phase 2	[5]
muramyl dipeptide	DM4FR71	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Pattern recognition receptor NOD2 (NOD2)	TTYPUHA	NOD2_HUMAN	Modulator	[2]
Retinoic acid-inducible gene-1 (RIG-1)	TTVB0O3	DDX58_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02751996) A Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic HBV (ACHIEVE). U.S. National Institutes of Health.
2	Company reprot (Spring Bank Pharmaceuticals) (drug: SB 9200)
3	Clinical pipeline report, company report or official report of CureVac.
4	National Cancer Institute Drug Dictionary (drug name RGT100).
5	DOI: 10.1371/journal.pone.0087712
6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1763).